ASH Clinical News | Page 31

NEARLY A 1-YEAR IMPROVEMENT IN MEDIAN PFS

(23.0 MONTHS VS 11.1 MONTHS; HR=0.16; 95% CI, 0.11-0.24; P<0.0001)1
SIGNIFICANTLY SUPERIOR PFS: GAZYVA in combination with Clb
more than doubled median PFS vs Clb monotherapy1
1.0
HR=0.16; 95%
CI, 0.11-0.24;
P<0.0001

0.9
0.8

84%
risk
reduction

0.7

PFS

0.6
0.5
0.4
0.3

11.1

0.2
GAZYVA + chlorambucil (n=238)
Chlorambucil (n=118)

0.1

23.0

0.0

GAZYVA
+ chlorambucil
Chlorambucil

0
No. at risk

3

6

9

12

15

18

21

24

27

Time (months)

238

208

201

146

111

69

39

16

2

0

118

91

76

46

21

6

2

0

0

0

PFS, progression-free survival; Clb, chlorambucil; HR, hazard ratio; CI, confidence interval.
CLL-11 Trial Design1: GAZYVA, in combination with chlorambucil, was evaluated in a Phase III, open-label, multicenter, 3-arm, randomized, parallel-group
comparative study in patients with previously untreated CD20+ chronic lymphocytic leukemia and coexisting medical c